Fewer than one in 10 individuals that would benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it releases its initial guidance on the medications.
With over a billion individuals worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
According to forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with comprehensive and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the jabs that can help people shift substantial weight, explains the body.
GLP-1 Therapy Shortage
Even under the current most optimistic scenario, the manufacturing of such drugs could only cover about 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation urges countries and companies to increase access, via strategies including voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Drugs Function
GLP-1 drugs mimick a biological compound to slow digestion, suppress the appetite and enhance feelings of fullness so users reduce food intake.
Patients typically see weight reduction after several weeks of commencing the regular doses.
Studies points to people may see weight return after a year of halting the medication, as their typical appetite come back.
To be overweight or obese elevates your chance for developing health problems, including type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the WHO.
